Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00815607
Recruitment Status : Completed
First Posted : December 30, 2008
Last Update Posted : July 18, 2013
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to test the safety of an investigational combination drug/immunotherapy for the treatment of Stage III/IV melanoma.

Condition or disease Intervention/treatment Phase
Melanoma Drug: INXN-1001 Biological: INXN-3001 Phase 1

Detailed Description:
This study will examine the effects of an oral Activator Ligand administration to modulate the timing of gene expression of human IL-12 by adenovirus-transduced dendritic cells injected into tumors.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b' Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12(INXN-3001) in Response to an Oral Activator Ligand in Patients With Unresectable Stage III C or IV Malignant Melanoma
Study Start Date : April 2009
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Intervention Details:
  • Drug: INXN-1001
    Capsules given once daily for 14 days for 3 treatment cycles.
  • Biological: INXN-3001
    Intratumoral injection

Primary Outcome Measures :
  1. Physical examinations, vital signs, serum chemistry, urinalysis, hematology, adverse events, and objective response rate, as assessed by diagnostic CT scans [ Time Frame: throughout the study ]

Secondary Outcome Measures :
  1. PK of oral Activator Ligand, Immunologic responses, particularly frequency of CTLs and Tregs and hIL-12 and other cytokine levels in injected target tumor(s) and in peripheral blood, Efficacy. [ Time Frame: throughout the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or females of all races ≥ 18 years of age and ≤ 75 years of age;
  2. Unresectable Stage III C (in transit) or Stage IV melanoma (M1a, M1b, M1c with LDH ≤ 2x ULN), arising from primary cutaneous, mucosal, or subungual melanoma of any tumor thickness or from an unknown primary site;
  3. A minimum of 2-3 accessible nonvisceral lesions (longest diameter ≤3 cm) or palpable tumor-involved lymph nodes (longest diameter ≤5 cm) for intratumoral injections (INXN-3001) and biopsies;
  4. ECOG performance status of 0 or 1;
  5. Patients without visible brain metastases as assessed by contrast-enhanced MRI scan within 6 weeks prior to receiving study treatment;
  6. Adequate baseline hematological and organ function, assessed by laboratory values within 42 days (6 weeks) prior to study entry and prior to repeat treatment cycles with INXN-1001 as follows: hemoglobin ≥ 10 g/L, granulocytes > 2500/mm3, lymphocytes > 1000/ mm3, platelets > 100,000/ mm3, serum creatinine < 1.5 x ULN, AST, ALT, alkaline phosphatase < 2.5 x ULN, LDH ≤ 2 x ULN, serum bilirubin < 1.5 x ULN, absolute neutrophils > 500/ mm3;
  7. An expected survival of at least approximately 6 months in the opinion of the investigator (as assessed mainly by performance status);
  8. Females must be post-menopausal or surgically sterile or practice effective contraception; Men who are not surgically sterile and whose partners are not post-menopausal or surgically sterile must practice effective contraception;
  9. Normal coagulation parameters as measured by PT/PTT;
  10. Signed, IRB-approved voluntary written informed consent.

Exclusion Criteria:

  1. Active, acute viral, bacterial, or fungal infections requiring specific therapy;
  2. HIV-infection due to concerns about ability to mount an effective immune response;
  3. Active autoimmune disease requiring steroids (>10 mg prednisolone or comparable) or other immunosuppressive therapy;
  4. Patients with detectable brain metastases at the time of screening (or within 6 weeks prior to receiving study treatment), as assessed by contrast-enhanced MRI scans;
  5. Patients with one or more lesion(s) > 3cm (LD) or palpable, tumor-involved lymph node(s) >5 cm (LD);
  6. Patients with a hemoglobin of < 10 g/L;
  7. Presence of Stage IV visceral metastases or other distant metastases if LDH >2 x ULN;
  8. Patients who have previously been treated with INXN-3001 and INXN-1001;
  9. Recipients of organ allografts;
  10. Other concurrent, clinically active malignant disease, with the exception of other cancers of the skin;
  11. Less than 30 days (before the first dose of study medication) have elapsed since the completion of prior chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any first line therapy;
  12. Clinically significant cerebrovascular disease;
  13. History of or concurrent severe cardiac insufficiency (New York Heart Association Class III or IV) or coronary artery disease;
  14. QTc interval of >470 ms on screening;
  15. Inability to measure the QT interval due to conduction abnormalities such as Bundle Branch Block (left or right) or persistent cardiac arrhythmia e.g. atrial fibrillation, or cardiac pacemaker;
  16. Long QT syndrome or family history of sudden cardiac death in young family members;
  17. Concomitant use of medication known to affect ventricular repolarization;
  18. Cardiac comorbidity such as a left ventricular ejection fraction <45%, myocardial infarction, persistent angina, or cardiac surgery within 3 months prior to enrollment;
  19. Uncontrollable hypertension (>150 mm Hg systolic or >100 mm Hg diastolic);
  20. Acute medical conditions such as ischemic heart or lung disease that may be considered an unacceptable anesthetic or operative risk;
  21. History of or current bleeding or uncorrected clotting disorders;
  22. Concurrent immunosuppressive therapy such as corticosteroids (>10mg prednisolone or comparable) and cyclosporin A;
  23. Concurrent investigational treatments, or treatment with any investigational treatment within the past 30 days (prior to the first dose of study medication);
  24. Concurrent medications that are metabolized by the CYP 3A4 pathway;
  25. Females who are lactating or pregnant;
  26. A Body Mass Index (BMI) greater than or equal to 40 kg/m2; aa. Patients who have a history of hypersensitivity that may relate to any component of the product, e.g. to benzoic acid that might be related to INXN-1001, which contains two benzene rings; bb. Any medical or psychiatric condition which, in the opinion of the investigator, would unacceptably reduce the safety or delivery of the proposed treatment, or would preclude obtaining voluntary informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00815607

United States, California
The Angeles Clinic and Research Institute
Santa Monica, California, United States, 90404
United States, Delaware
Helen F. Graham Cancer Center
Newark, Delaware, United States, 19713
United States, Georgia
• Nancy N. and J.C. Lewis Cancer Center & Research Pavilion at St. Joseph/Candles
Savannah, Georgia, United States, 31405
United States, Illinois
Oncology Specialists, S.C.
Park Ridge, Illinois, United States, 60068
United States, Indiana
Goshen Clinic
Goshen, Indiana, United States, 46526
United States, Montana
Billings Clinic
Billings, Montana, United States, 59101
United States, Pennsylvania
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
United States, Texas
Mary Crowley Cancer Research Centers
Dallas, Texas, United States, 75201
Sponsors and Collaborators
Study Director: Andrew Marsh ZIOPHARM Oncology

Responsible Party: Ziopharm Identifier: NCT00815607     History of Changes
Other Study ID Numbers: RTS-M101B'
NIH OBA 0710-881
First Posted: December 30, 2008    Key Record Dates
Last Update Posted: July 18, 2013
Last Verified: July 2013

Keywords provided by Ziopharm:

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas